Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

<< Previous

Bullboard Posts

Comment by SPCEO1on Nov 27, 2024 4:45pm

114 Views

Post# 36334497

RE:RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Here are three positions THTX is currently hiring as indicated on LinkedIn. It would be odd if they were hiring people in the face of a complete loss of Egrifta revenue in Q1 without something else happening that would assure them of their financial well-being in the meantime.

I am not sure how it is that THTX is not required to inform the market regarding the Egrifta supply situation, unless there is some other new piece of related info that is not disclosable yet. I am not sure what that other piece of info might be but refinancing the Marathon debt might be part of it. We will just have to wait and see. Hopefully, the wait will not be too much longer as it is not hard to come up with a disaster scenario on the Egrifta shortage/Marathon front. With these hiring efforts, however, it looks like they already are confident no disaster will occur,